Oxycodone News and Research

RSS

QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

19 Mar 2012

New NPS information on dextropropoxyphene: recommendations and alternatives

NPS has published information online for prescribers to help them prepare for the TGA’s cancellation of Capadex and Paradex, two of the four medicines available in Australia containing dextropropoxyphene.

1 Mar 2012

Report identifies patterns in misuse of illicit and prescription drugs among young adults

A new report from researchers at the Drexel University School of Public Health identifies patterns in the misuse of illicit drugs among young adults who also misuse prescription drugs.

28 Feb 2012

Mass. bill would mandate docs to check database before prescribing pain meds

The legislation is expected to come up for a vote in the Massachusetts Senate Thursday. In Florida, the legislature killed a bill to take away prescription rights from doctors awaiting trial on pill-trafficking charges.

2 Feb 2012

Array second quarter revenue increases to $23.2 million

Array BioPharma Inc. today reported financial results for the second quarter of fiscal 2012.

31 Jan 2012

Powerful painkiller on its way to the market: Experts worry about addiction woes

Drug makers are on their way to a pure, more powerful version of the nation’s second most-abused medicine, which has addiction experts worried that it could spur a new wave of abuse. The new pills contain the highly addictive painkiller hydrocodone, packing up to 10 times the amount of the drug as existing medications such as Vicodin.

28 Dec 2011

Actavis enters LOI with QRxPharma to commercialize MoxDuo IR in the U.S.

Actavis Group, the international generic pharmaceuticals company, today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited to commercialize MoxDuo IR in the United States.

21 Dec 2011

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Nektar Therapeutics today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in healthy subjects.

14 Dec 2011

Combination of cannabinoids and opiates could help reduce chronic pain

A UCSF study suggests patients with chronic pain may experience greater relief if their doctors add cannabinoids - the main ingredient in cannabis or medical marijuana - to an opiates-only treatment. The findings, from a small-scale study, also suggest that a combined therapy could result in reduced opiate dosages.

7 Dec 2011

State roundup: Wis. physician shortage predicted; CVS blacklisting some Fla. docs; 'Ambitious' Baltimore HIV initiative

The state needs to train or recruit an additional 100 physicians a year through 2030 to meet the projected demand for health care, according to a new Wisconsin Hospital Association report. ... The group says the state must act immediately ... Primary care physicians - doctors who specialize in family and internal medicine and pediatrics - will account for 80 percent of the projected shortage.

1 Dec 2011

Older patients less likely to receive pain medication in hospital EDs

A new study finds that people 75 years old or older are less likely to receive any pain medication in hospital emergency departments than middle aged people - those between 35 and 54 years old.

13 Nov 2011

QRxPharma receives FDA written acceptance for review of MoxDuo IR NDA

QRxPharma Limited announced today it received written acceptance from the United States Food and Drug Administration (FDA) for review of the MoxDuo IR New Drug Application (NDA) filed earlier this year.

9 Nov 2011

QRxPharma receives date for US pain drug launch, pending approval

Australian pain-relief drug developer QRxPharma (QRX) has announced today that they have received from the US Food & Drug Adminstration.

8 Nov 2011

$Narcotic analgesics increase risk of falls and fractures among elderly$

Narcotic analgesics increase risk of falls and fractures among elderly

Falls and fractures among senior citizens have increased since rofecoxib was removed from the market in 2004, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Viewpoints: GOP intransigence on super committee; taxing health benefits would backfire; the need for care in defining essential benefits

There may be logic to Speaker John Boehner's insidious intransigence. Republicans keep saying no and Democrats keep offering more concessions. Super committee Republicans suggested instead a package based largely on cuts in Medicare, Medicaid and Social Security, combined with magical hundreds of billions they say would be produced by slashing assistance to the elderly and the vulnerable, by selling off government assets, and by the growth sparked by tax cuts.

3 Nov 2011

Americans overdosing on prescription pain killers

According to figures released by the Centers for Disease Control and Prevention (CDC) 40 Americans die from prescription painkiller abuse each day. Overdoses of opioid prescription drugs now kill more people in the U.S. than do overdoses from heroin and cocaine combined the report says. Twelve million Americans say they abused prescription drugs in the last year.

2 Nov 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Researchers control itch without dulling morphine's pain-killing effects

Itching is one of the most prevalent side effects of powerful, pain-killing drugs like morphine, oxycodone and other opioids. The opiate-associated itch is so common that even women who get epidurals for labor pain often complain of itching. For many years, scientists have scratched their own heads about why drugs that so effectively suppress pain also induce itch.

14 Oct 2011

Research roundup: Health disparities; Prescription drug abuse in Medicare Part D; Medicaid's role for HIV patients

Achieving Equity In Health -- This policy brief examines the outlining factors that cause disparities in the health care system and focuses on the October issue of the journal, which is devoted to research on the subject.

7 Oct 2011

Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.

27 Sep 2011